MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

1.340 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
3 Cash-Burning Stocks We Approach with Caution
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them... 
Via StockStory
News headline image
Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell PACB and 1 Stock to Buy Instead
Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was partly due ... 
Via StockStory
Topics Bankruptcy
News headline image
1 of Wall Street’s Favorite Stocks to Own for Decades and 2 We Brush Off
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
Pacific Biosciences (NASDAQ:PACB) Shares Drop After Q2 Revenue Miss ↗
Via Chartmill
News headline image
1 Healthcare Stock to Target This Week and 2 Facing Headwinds
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity ↗
Pacific Biosciences of California (NASDAQ:PACB) reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in... 
Via MarketBeat
News headline image
5 Must-Read Analyst Questions From PacBio’s Q2 Earnings Call
PacBio’s second quarter was met with a negative market reaction, as sales and adjusted earnings per share both fell short of Wall Street’s expectations. Mana... 
Via StockStory
Topics Earnings
News headline image
PACB Q2 Deep Dive: Leadership Transition and SPRQ-Nx Rollout Shape Outlook
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 1.9% year o... 
Via StockStory
News headline image
Pacific Biosciences of California Q2 Earnings Call Highlights ↗
Pacific Biosciences of California (NASDAQ:PACB) reported second-quarter 2026 revenue of $39 million, roughly flat from $39.8 million a year earlier, while announcing an immediate leadership transition... 
Via MarketBeat
Topics Earnings
News headline image
PacBio (NASDAQ:PACB) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 1.9% year o... 
Via StockStory
News headline image
PacBio (PACB) To Report Earnings Tomorrow: Here Is What To Expect
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting results this Wednesday afternoon. Here’s what you need to know. PacBio mis... 
Via StockStory
News headline image
3 Russell 2000 Stocks That Fall Short
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
1 Russell 2000 Stock on Our Watchlist and 2 That Underwhelm
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
1 Small-Cap Stock Worth Investigating and 2 That Underwhelm
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks Walking a Fine Line
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
3 Cash-Burning Stocks with Questionable Fundamentals
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them... 
Via StockStory
News headline image
3 Unprofitable Stocks That Concern Us
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofi... 
Via StockStory
News headline image
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ:PACB) and i... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
From Blank Bio
Via Business Wire
News headline image
1 Stock Under $10 to Keep an Eye On and 2 We Avoid
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying busi... 
Via StockStory
News headline image
Why PacBio (PACB) Shares Are Getting Obliterated Today
What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) fell 14.2% in the afternoon session after the company reported mixe... 
Via StockStory
Topics Earnings Economy
News headline image
PacBio (PACB) Q1 2026 Earnings Call Transcript ↗
PacBio (PACB) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
PACB Q1 Deep Dive: Consumables Growth and Clinical Adoption Offset Instrument Weakness
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q1 CY2026, with sales flat year on year a... 
Via StockStory
News headline image
Pacific Biosciences of California Q1 Earnings Call Highlights ↗
Pacific Biosciences of California (NASDAQ:PACB) reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
3 Small-Cap Stocks We Find Risky
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
Topics Artificial Intelligence
News headline image
PacBio (NASDAQ:PACB) Misses Q1 CY2026 Sales Expectations
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q1 CY2026, with sales flat year on year a... 
Via StockStory
Topics Artificial Intelligence
News headline image
PacBio (PACB) Q1 Earnings Report Preview: What To Look For
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting earnings this Thursday after market hours. Here’s what investors should kn... 
Via StockStory
News headline image
1 Cash-Burning Stock with Solid Fundamentals and 2 We Turn Down
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story